Trial Search Results

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone marrow Transplantation are enrolling patients into a research study to determine if donor stem cells given after a living related one Haplotype match kidney transplantation will change the immune system such that immunosuppressive drugs can be completely withdrawn.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

Intervention(s):

  • Drug: Immune Tolerance

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. All consenting adults who are 18 to 60 years, living donor transplant candidates and
   have a happlotype related living donor or > 2 HLA antigen matched, unrelated, living
   donor (including at least one HLA-DR antigen match pus at least one antigen match of
   either HLA-A or HLA-B).

   2. Patients who agree to participate in the study and sign an Informed Consent.

   3. Patients who have no known contraindication to administration of rabbit ATG or
   radiation.

   4. Males and females of reproductive potential who agree to practice a reliable form of
   contraception for at least 24 months posttransplant.

   5. ABO compatible.

Exclusion Criteria:

   1. Previous treatment with rabbit ATG or a known allergy to rabbit proteins.

   2. History of malignancy with the exception of non-melanoma skin malignancies.

   3. Pregnant women or nursing mothers.

   4. Serological evidence of HIV, Hepatitis B or Hepatitis C infection.

   5. Seronegative for Epstein-Barr virus, if donor is seropositive.

   6. Leukopenia (with a white blood cell count < 3000/mm3) or thrombocytopenia (with a
   platelet count < 100,000/mm3).

   7. Panel Reactive Antibody greater than 80% or demonstration of donor specific antibody
   (DSA).

   8. Prior organ transplantation.

   9. High risk of primary kidney disease recurrence (e.g atypical HUS). However, patients
   with primary FSGS will not be excluded.

Ages Eligible for Study

18 Years - 60 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Asha Shori, CCRP
650-736-0245
Recruiting